NAV
$26.44
AUM
$4.2M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +5.27% | +9.20% | +7.63% | +16.68% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | NVO | Novo Nordisk AS ADR | 14.64% |
| 2 | LLY | Eli Lilly and Co | 13.80% |
| 3 | ARWR | Arrowhead Pharmaceuticals Inc | 6.04% |
| 4 | AMGN | Amgen Inc | 5.95% |
| 5 | 4519.T | Chugai Pharmaceutical Co Ltd | 5.38% |
| 6 | REGN | Regeneron Pharmaceuticals Inc | 5.35% |
| 7 | ROP.SW | Roche Holding AG Ordinary Shares new | 5.07% |
| 8 | 1801.HK | Innovent Biologics Inc | 5.02% |
| 9 | MRK | Merck & Co Inc | 4.94% |
| 10 | PFE | Pfizer Inc | 4.70% |
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
Inception Date: 2024-05-20